750 related articles for article (PubMed ID: 31361567)
1. The use of off-label medications in substance abuse treatment programs.
Paino M; Aletraris L; Roman PM
Subst Abus; 2020; 41(3):340-346. PubMed ID: 31361567
[No Abstract] [Full Text] [Related]
2. The transition to medication adoption in publicly funded substance use disorder treatment programs: organizational structure, culture, and resources.
Knudsen HK; Roman PM
J Stud Alcohol Drugs; 2014 May; 75(3):476-85. PubMed ID: 24766760
[TBL] [Abstract][Full Text] [Related]
3. Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States.
Abraham AJ; Knudsen HK; Rieckmann T; Roman PM
J Stud Alcohol Drugs; 2013 Mar; 74(2):258-65. PubMed ID: 23384373
[TBL] [Abstract][Full Text] [Related]
4. Early adoption of injectable naltrexone for alcohol-use disorders: findings in the private-treatment sector.
Abraham AJ; Roman PM
J Stud Alcohol Drugs; 2010 May; 71(3):460-6. PubMed ID: 20409441
[TBL] [Abstract][Full Text] [Related]
5. Adoption and diffusion of evidence-based addiction medications in substance abuse treatment.
Heinrich CJ; Cummings GR
Health Serv Res; 2014 Feb; 49(1):127-52. PubMed ID: 23855719
[TBL] [Abstract][Full Text] [Related]
6. The Relationship Between Client Characteristics and Wraparound Services in Substance Use Disorder Treatment Centers.
Paino M; Aletraris L; Roman P
J Stud Alcohol Drugs; 2016 Jan; 77(1):160-9. PubMed ID: 26751366
[TBL] [Abstract][Full Text] [Related]
7. Organizational Predictors and Use of Evidence-Based Practices in Adolescent Substance Abuse Treatment.
Paino M; Aletraris L; Roman PM
Subst Abus; 2015; 36(4):462-9. PubMed ID: 25257691
[TBL] [Abstract][Full Text] [Related]
8. Experiences with Patient Refusal of Off-Label Prescribing of Psychotropic Medications to Children and Adolescents in Japan.
Tsujii N; Saito T; Izumoto Y; Usami M; Okada T; Negoro H; Iida J
J Child Adolesc Psychopharmacol; 2016 Sep; 26(7):642-5. PubMed ID: 26103533
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapies for co-occurring substance use and bipolar disorders: A systematic review.
Coles AS; Sasiadek J; George TP
Bipolar Disord; 2019 Nov; 21(7):595-610. PubMed ID: 31077521
[TBL] [Abstract][Full Text] [Related]
10. Medication-assisted treatment for substance use disorders within a national community health center research network.
Rieckmann T; Muench J; McBurnie MA; Leo MC; Crawford P; Ford D; Stubbs J; O'Cleirigh C; Mayer KH; Fiscella K; Wright N; Doe-Simkins M; Cuddeback M; Salisbury-Afshar E; Nelson C
Subst Abus; 2016; 37(4):625-634. PubMed ID: 27218678
[TBL] [Abstract][Full Text] [Related]
11. Barriers to the implementation of medication-assisted treatment for substance use disorders: the importance of funding policies and medical infrastructure.
Knudsen HK; Abraham AJ; Oser CB
Eval Program Plann; 2011 Nov; 34(4):375-81. PubMed ID: 21371752
[TBL] [Abstract][Full Text] [Related]
12. Growth in spending on substance use disorder treatment services for the privately insured population.
Thomas CP; Hodgkin D; Levit K; Mark TL
Drug Alcohol Depend; 2016 Mar; 160():143-50. PubMed ID: 26781063
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy of dual substance abuse and dependence.
Kenna GA; Nielsen DM; Mello P; Schiesl A; Swift RM
CNS Drugs; 2007; 21(3):213-37. PubMed ID: 17338593
[TBL] [Abstract][Full Text] [Related]
14. Adoption of injectable naltrexone in U.S. substance use disorder treatment programs.
Aletraris L; Bond Edmond M; Roman PM
J Stud Alcohol Drugs; 2015 Jan; 76(1):143-51. PubMed ID: 25486403
[TBL] [Abstract][Full Text] [Related]
15. Provision of onsite HIV Services in Substance Use Disorder Treatment Programs: A Longitudinal Analysis.
Aletraris L; Roman PM
J Subst Abuse Treat; 2015 Oct; 57():1-8. PubMed ID: 25934459
[TBL] [Abstract][Full Text] [Related]
16. Off-label use of cardiovascular medications in children hospitalized with congenital and acquired heart disease.
Pasquali SK; Hall M; Slonim AD; Jenkins KJ; Marino BS; Cohen MS; Shah SS
Circ Cardiovasc Qual Outcomes; 2008 Nov; 1(2):74-83. PubMed ID: 20031793
[TBL] [Abstract][Full Text] [Related]
17. Perceptions of the state policy environment and adoption of medications in the treatment of substance use disorders.
Knudsen HK; Abraham AJ
Psychiatr Serv; 2012 Jan; 63(1):19-25. PubMed ID: 22227755
[TBL] [Abstract][Full Text] [Related]
18. Predictors of polypharmacy and off-label prescribing of psychotropic medications: a national survey of child and adolescent psychiatrists.
Kearns MA; Hawley KM
J Psychiatr Pract; 2014 Nov; 20(6):438-47. PubMed ID: 25406048
[TBL] [Abstract][Full Text] [Related]
19. Patterns of organization and management in private and public substance abuse treatment programs.
Roman PM; Ducharme LJ; Knudsen HK
J Subst Abuse Treat; 2006 Oct; 31(3):235-43. PubMed ID: 16996386
[TBL] [Abstract][Full Text] [Related]
20. Off-label use of oral fluoroquinolone antibiotics in outpatient settings in the United States, 2006 to 2012.
Almalki ZS; Alahmari AK; Guo JJ; Cavanaugh TM
Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1042-51. PubMed ID: 27133913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
